IL159285A0 - Use of lhrh-antagonists in doses that do not cause castration for the improvement of t-cell mediated immunity - Google Patents

Use of lhrh-antagonists in doses that do not cause castration for the improvement of t-cell mediated immunity

Info

Publication number
IL159285A0
IL159285A0 IL15928502A IL15928502A IL159285A0 IL 159285 A0 IL159285 A0 IL 159285A0 IL 15928502 A IL15928502 A IL 15928502A IL 15928502 A IL15928502 A IL 15928502A IL 159285 A0 IL159285 A0 IL 159285A0
Authority
IL
Israel
Prior art keywords
lhrh
antagonists
doses
improvement
cell mediated
Prior art date
Application number
IL15928502A
Other languages
English (en)
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of IL159285A0 publication Critical patent/IL159285A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15928502A 2001-07-31 2002-07-30 Use of lhrh-antagonists in doses that do not cause castration for the improvement of t-cell mediated immunity IL159285A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10137174A DE10137174A1 (de) 2001-07-31 2001-07-31 Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
PCT/EP2002/008459 WO2003011314A2 (en) 2001-07-31 2002-07-30 Use of lhrh-antagonists for the improvement of t-cell mediated immunity

Publications (1)

Publication Number Publication Date
IL159285A0 true IL159285A0 (en) 2004-06-01

Family

ID=7693650

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15928502A IL159285A0 (en) 2001-07-31 2002-07-30 Use of lhrh-antagonists in doses that do not cause castration for the improvement of t-cell mediated immunity

Country Status (19)

Country Link
EP (1) EP1414481B1 (de)
JP (1) JP2005500348A (de)
KR (1) KR20040028957A (de)
CN (1) CN1525865A (de)
AR (1) AR034954A1 (de)
AT (1) ATE315400T1 (de)
BR (1) BR0211498A (de)
CA (1) CA2452524A1 (de)
DE (2) DE10137174A1 (de)
HR (1) HRP20040186B1 (de)
HU (1) HUP0401634A2 (de)
IL (1) IL159285A0 (de)
MX (1) MXPA04000870A (de)
NO (1) NO20040350L (de)
NZ (1) NZ531263A (de)
PL (1) PL364492A1 (de)
RU (1) RU2004106545A (de)
WO (1) WO2003011314A2 (de)
ZA (1) ZA200309889B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL147138A0 (en) * 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
EP1891964A1 (de) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Anwendung von Anfangsdosen von LHRH-Analogen und Erhaltungsdosen von LHRH-Antagonisten zur Behandlung von hormonabhängigen Krebsarten und entsprechende Kits
JP2010538989A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト Ｈｂｖ感染等の治療における治療剤としてのｎｆ−カッパーｂインヒビターｓｎ５０の使用、及び必要に応じたアンギオテンシンｉｉｉの使用
WO2009033725A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of human neuropeptide as a therapeutic agent
EP2095818A1 (de) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Verwendung von LHRH-Antagonisten in nicht-kastrierenden Dosen
EP2379099A1 (de) * 2009-01-22 2011-10-26 Maatschap Interne Geneeskunde Rijnstate Verfahren zur prophylaxe oder behandlung von hitzewallungen
WO2016030334A2 (en) 2014-08-26 2016-03-03 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions
CN107007814B (zh) * 2016-11-04 2020-03-17 中国科学院昆明动物研究所 西曲瑞克在制备治疗艾滋病的药物中的应用
CN108066763A (zh) * 2017-12-21 2018-05-25 陈敏 Pcsk9抑制剂在制备治疗t细胞介导的炎症免疫性疾病药中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2067123A1 (en) * 1989-09-25 1991-03-26 Esther M. Sternberg Evaluative means for detecting inflammatory reactivity and for predicting response to stress
DE4320201A1 (de) * 1993-06-18 1995-01-12 Asta Medica Ag Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation
DE4342091A1 (de) * 1993-12-09 1995-06-14 Asta Medica Ag Erzeugnisse zur Anwendung von initial hohen Dosen von Cetrorelix und Herstellung einer Kombinationspackung zur Verwendung bei Therapie von Krankheiten
WO1996003138A1 (en) * 1994-07-22 1996-02-08 The Medical College Of Hampton Roads Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
AU3361695A (en) * 1994-08-10 1996-03-07 Dezso Gaal Novel gnrh analogues with antitumour effects and pharmaceutical compositions thereof
AU4459196A (en) * 1995-01-23 1996-08-14 Takeda Chemical Industries Ltd. Sustained-release preparation and use
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
US6054432A (en) * 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer
EP1032397A1 (de) * 1997-11-24 2000-09-06 University Of Florida Research Foundation, Inc. Testosterone inhibitoren und verwendung zum neuronalschutz
US20020071829A1 (en) * 1999-04-15 2002-06-13 Richard Boyd Normalization of defective T cell responsiveness through manipulation of thymic regeneration
WO2001078780A1 (fr) * 2000-04-13 2001-10-25 Takeda Chemical Industries, Ltd. Agents preventifs/remedes pour la maladie d'alzheimer
CA2462046A1 (en) * 2000-10-13 2002-04-18 Monash University Improvement of graft acceptance through manipulation of thymic regeneration
RU2319501C2 (ru) * 2001-04-30 2008-03-20 Центарис Гмбх Способ лечения болезни альцгеймера
US20030144203A1 (en) * 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence

Also Published As

Publication number Publication date
HUP0401634A2 (hu) 2004-12-28
MXPA04000870A (es) 2004-06-03
ZA200309889B (en) 2004-02-19
CN1525865A (zh) 2004-09-01
PL364492A1 (en) 2004-12-13
EP1414481B1 (de) 2006-01-11
JP2005500348A (ja) 2005-01-06
AR034954A1 (es) 2004-03-24
DE10137174A1 (de) 2003-02-13
WO2003011314A2 (en) 2003-02-13
EP1414481A2 (de) 2004-05-06
DE60208701D1 (de) 2006-04-06
CA2452524A1 (en) 2003-02-13
WO2003011314A3 (en) 2003-10-16
NO20040350L (no) 2004-01-26
RU2004106545A (ru) 2005-04-10
KR20040028957A (ko) 2004-04-03
DE60208701T2 (de) 2006-08-10
HRP20040186B1 (en) 2007-05-31
ATE315400T1 (de) 2006-02-15
BR0211498A (pt) 2004-08-17
NZ531263A (en) 2005-05-27
HRP20040186A2 (en) 2004-08-31

Similar Documents

Publication Publication Date Title
AU6755101A (en) Device for producing dental workpieces
EP1323393A4 (de) Mundstück für eine orthodontische behandlung und vorrichtung für eine orthodontische behandlung mit dem mundstück
PL388076A1 (pl) Doustna postać dawki o przedłużonym uwalnianiu oksykodonu i jej zastosowanie
GB0108213D0 (en) Medicament dispenser
GB0114175D0 (en) Medicament dispenser
GB0108208D0 (en) Medicament dispenser
HK1080011A1 (en) Molded article for dental use
WO2002007710A3 (en) Delivery device
IL159285A0 (en) Use of lhrh-antagonists in doses that do not cause castration for the improvement of t-cell mediated immunity
EP1369362A4 (de) Zuführvorrichtung für artikel
GB0026061D0 (en) Adjustable stop apparatus
PL342829A1 (en) Bioenergetical therapeutic device
AU144325S (en) Therapy device
GB0124071D0 (en) Improvement in the administration of high boiling point aneasthetics
SG91934A1 (en) Bonding apparatus
GB2365336B (en) Delivery device
GB2364602B (en) Therapeutic device
AU144305S (en) Dental device
GB0128138D0 (en) Pharmaceutical use
EP1394427A4 (de) Tischvorrichtung
GB0123378D0 (en) Unit dose products
GB0110485D0 (en) Medicament dispenser
GB0112993D0 (en) The funnel waiter
CA90906S (en) Medical device interface
GB2363602B (en) Feed singulation device